Collegium pharmaceutical, inc. (COLL)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues
Product revenues, net

76,511

74,203

72,942

75,040

74,516

73,427

70,176

73,061

63,749

10,794

11,950

3,560

2,172

1,303

408

-

-

-

-

-

-

-

-

-

-

Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)

27,229

-

-

-

45,476

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible asset amortization

10,295

-

-

-

3,688

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of products revenues

37,524

49,088

46,754

48,654

49,164

29,726

46,007

46,838

43,106

1,094

553

577

371

184

29

-

-

-

-

-

-

-

-

-

-

Gross profit

38,987

-

-

-

25,352

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development

2,666

2,398

2,491

2,459

2,992

2,249

1,907

2,237

2,268

2,194

2,069

2,179

2,130

3,331

3,254

4,301

4,062

1,531

3,358

1,641

1,445

2,307

5,818

3,565

3,269

Selling, general and administrative

31,260

25,090

30,072

28,935

32,352

30,451

33,448

31,279

31,582

25,089

22,758

22,062

22,847

25,367

23,567

20,173

11,525

7,906

5,907

2,934

2,185

1,020

687

523

476

Total costs and expenses

33,926

76,576

79,317

80,048

35,344

62,426

81,362

80,354

76,956

28,377

25,380

24,818

25,348

28,882

26,850

24,474

15,587

9,437

9,265

4,575

3,630

3,327

6,505

4,088

3,745

Income (loss) from operations

5,061

-2,373

-6,375

-5,008

-9,992

11,001

-11,186

-7,293

-13,207

-17,583

-13,430

-21,258

-23,176

-27,579

-26,442

-24,474

-15,587

-9,437

-9,265

-4,575

-3,630

-3,327

-6,505

-4,088

-3,745

Interest expense

4,823

211

228

236

234

2,404

5,868

6,158

5,700

-

-

-

-

-

-

-

-

-

97

99

-

-

-

-

-

Interest income

212

383

494

532

526

489

552

391

255

180

167

137

98

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-155

-

-

-

-

Gain on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

91

-

-

-

-

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-2

-46

-66

-88

-97

-99

-64

-142

-51

-29

-30

Net income (loss)

450

-2,201

-6,109

-4,712

-9,700

9,086

-16,502

-13,060

-18,652

-17,403

-13,263

-21,121

-23,078

-27,559

-26,444

-24,520

-15,653

-9,525

-9,362

-4,674

-3,694

-3,469

-6,556

-4,117

-3,775

Loss per share - basic and diluted

-

-0.07

-0.18

-0.14

-

-

-

-

-

-0.54

-0.45

-0.72

-0.79

-1.02

-1.13

-1.05

-0.68

-

-0.46

-0.45

-

-4.50

-7.85

-5.33

-5.03

Weighted-average shares - basic and diluted (in shares)

-

33,600

33,481

33,397

-

-

-

-

-

32,485

29,753

29,441

29,350

27,100

23,460

23,417

23,130

-

20,531

11,791

-

955

940

926

912

Earnings (loss) per share - basic (in dollars per share)

0.01

-

-

-

-0.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.34

-

-

-

-

Weighted-average shares - basic (in shares)

34,100

-

-

-

33,331

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,001

-

-

-

-

Earnings (loss) per share - diluted (in dollars per share)

0.01

-

-

-

-0.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.65

-

-

-

-

Weighted-average shares - diluted (in shares)

35,069

-

-

-

33,331

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,554

-

-

-

-